What is Boehringer Ingelheim's policy on clinical trial information disclosure?
Boehringer Ingelheim has a general policy of transparency with publication of clinical trial results. We recognize that there are important public health benefits associated with making clinical trial information more widely available to healthcare professionals and patients. Such disclosure, however, must maintain protection for intellectual property and contract rights as well as conform to the regulations in relevant countries.
Boehringer Ingelheim supports the joint global position of the research-based pharmaceutical industry published by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and is committed to the agreed principles.
Related content
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) clinical trials portal
Industry commitment to transparency in clinical trials
